In this issue:
Abrocitinib for atopic dermatitis
Tralokinumab for moderate-to-severe atopic dermatitis
Tralokinumab + topical corticosteroids for atopic dermatitis
Adverse events with dupilumab
Laboratory parameters in adolescents with atopic dermatitis on dupilumab
Bimekizumab for moderate-to-severe plaque psoriasis
Time to relapse after tildrakizumab withdrawal
Consensus statements on biosimilars for psoriasis
Please login below to download this issue (PDF)